PARTIAL
Research type
Research Study
Full title
The PARTIAL study: A randomised trial of the clinical and cost effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma
IRAS ID
318662
Contact name
Naeem Soomro
Contact email
Sponsor organisation
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
ISRCTN Number
ISRCTN11293415
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Each year 13,000 people in the UK are diagnosed with kidney cancer. Historically, many patients presented late with symptoms from large cancerous growths. In individuals with a normal kidney on the unaffected side, the standard treatment was to remove the entire affected kidney. Nowadays, most kidney cancers are found at an earlier stage when a scan is performed for an unrelated condition. These smaller cancers can either be treated by removing the entire affected kidney or just the portion of the kidney affected by the tumour. However removing just the kidney tumour is more difficult than removing the entire kidney. Partial kidney removal comes with a slightly greater risk of leaving some cancer behind requiring retreatment. Bleeding and urine leakage are also a risk with partial removal of the kidney. Nevertheless, partial kidney surgery remains attractive as these additional risks could be traded off with potential benefits from maintaining more kidney function. This may reduce the chances of developing kidney failure and requiring dialysis. Loss of kidney function is also associated with developing heart disease in the future. However, there are no high-quality successfully completed clinical trials comparing which approach is better. In patients with kidney cancer and a normal kidney on the other side, we plan to conduct a clinical trial to answer the question of whether partial removal of the kidney (partial nephrectomy) is better than removing the whole kidney (radical nephrectomy). Everyone that takes part on our study will have an equal chance of either partial or total removal of the kidney. We will compare the two treatments in terms of their effect over 2 years on how well the kidney(s) are working, quality of life, complication rates, survival and the use of NHS resources. The study will recruit 420 patients from 30 hospitals across the UK.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
22/SW/0171
Date of REC Opinion
12 Dec 2022
REC opinion
Further Information Favourable Opinion